These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36793278)

  • 1. Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes.
    Wu H; Lu Z; Chen R; Cai Q; Wang M; Zhang L; Zhu Z
    Front Endocrinol (Lausanne); 2023; 14():1098032. PubMed ID: 36793278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes.
    Thong KY; Gupta PS; Blann AD; Ryder RE
    Diabetes Res Clin Pract; 2015 Jul; 109(1):124-9. PubMed ID: 25937541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms.
    Ye J; Xu J; Wen W; Huang B
    Int J Clin Pract; 2022; 2022():1786559. PubMed ID: 36311486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high thyroid stimulating hormone level is associated with diabetic peripheral neuropathy in type 2 diabetes patients.
    Zhao W; Zeng H; Zhang X; Liu F; Pan J; Zhao J; Zhao J; Li L; Bao Y; Liu F; Jia W
    Diabetes Res Clin Pract; 2016 May; 115():122-9. PubMed ID: 26822260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of liraglutide vs. NPH in combination with metformin on blood glucose fluctuations assessed using continuous glucose monitoring in patients with newly diagnosed type 2 diabetes.
    Ma Z; Chen R; Liu Y; Yu P; Chen L
    Int J Clin Pharmacol Ther; 2015 Nov; 53(11):933-9. PubMed ID: 26365337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of GLP-1R rs2254336 and rs3765467 polymorphisms on gastrointestinal adverse reactions in type 2 diabetes patients treated with liraglutide.
    Long J; Liu Y; Duan Y; Li Y; Yang G; Ren Z; Tao W; Liu D
    Eur J Clin Pharmacol; 2022 Apr; 78(4):589-596. PubMed ID: 35034150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid stimulating hormone and free triiodothyronine are valuable predictors for diabetic nephropathy in patient with type 2 diabetes mellitus.
    Fei X; Xing M; Wo M; Wang H; Yuan W; Huang Q
    Ann Transl Med; 2018 Aug; 6(15):305. PubMed ID: 30211193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus.
    de Vries TI; Kappelle LJ; van der Graaf Y; de Valk HW; de Borst GJ; Nathoe HM; Visseren FLJ; Westerink J;
    Acta Diabetol; 2019 Apr; 56(4):431-440. PubMed ID: 30259116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
    Horowitz M; Aroda VR; Han J; Hardy E; Rayner CK
    Diabetes Obes Metab; 2017 May; 19(5):672-681. PubMed ID: 28058769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of risk factors for the development of type 2 diabetes mellitus complicated with Hashimoto's thyroiditis.
    Han M; Wu H; Yang W; Chen J
    BMC Endocr Disord; 2022 Jul; 22(1):173. PubMed ID: 35804367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
    Liu L; Chen J; Wang L; Chen C; Chen L
    Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide in Children and Adolescents with Type 2 Diabetes.
    Tamborlane WV; Barrientos-Pérez M; Fainberg U; Frimer-Larsen H; Hafez M; Hale PM; Jalaludin MY; Kovarenko M; Libman I; Lynch JL; Rao P; Shehadeh N; Turan S; Weghuber D; Barrett T;
    N Engl J Med; 2019 Aug; 381(7):637-646. PubMed ID: 31034184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    Marso SP; Daniels GH; Brown-Frandsen K; Kristensen P; Mann JF; Nauck MA; Nissen SE; Pocock S; Poulter NR; Ravn LS; Steinberg WM; Stockner M; Zinman B; Bergenstal RM; Buse JB; ;
    N Engl J Med; 2016 Jul; 375(4):311-22. PubMed ID: 27295427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Changes in Thyroid Hormones and Incident Type 2 Diabetes: A Seven-Year Longitudinal Study.
    Jun JE; Jee JH; Bae JC; Jin SM; Hur KY; Lee MK; Kim TH; Kim SW; Kim JH
    Thyroid; 2017 Jan; 27(1):29-38. PubMed ID: 27809684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?
    Moreno-Fernandez J; Garcia-Seco JA; Seco Segura AM; Garcia-Seco F; Rozas Moreno PJ; Aguirre Sanchez-Covisa M
    Prim Care Diabetes; 2020 Feb; 14(1):68-74. PubMed ID: 31171461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid Parameters and Kidney Disorder in Type 2 Diabetes: Results from the METAL Study.
    Chen Y; Zhang W; Wang N; Wang Y; Wang C; Wan H; Lu Y
    J Diabetes Res; 2020; 2020():4798947. PubMed ID: 32337292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Relationship Between Thyroid Function and the Prevalence of Type 2 Diabetes Mellitus in Euthyroid Subjects.
    Gu Y; Li H; Bao X; Zhang Q; Liu L; Meng G; Wu H; Du H; Shi H; Xia Y; Su Q; Fang L; Yu F; Yang H; Yu B; Sun S; Wang X; Zhou M; Jia Q; Guo Q; Chang H; Wang G; Huang G; Song K; Niu K
    J Clin Endocrinol Metab; 2017 Feb; 102(2):434-442. PubMed ID: 27906594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
    J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.
    Kajiwara M; Tanaka A; Kawasaki T; Nakao K; Sakamoto T; Toyoda S; Inoue T; Koga N; Node K
    J Cardiol; 2017 Mar; 69(3):511-517. PubMed ID: 27894787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.